Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
DTIL

DTIL - Precision BioSciences Inc Stock Price, Fair Value and News

9.41USD+0.01 (+0.11%)Market Closed

Market Summary

DTIL
USD9.41+0.01
Market Closed
0.11%

DTIL Stock Price

View Fullscreen

DTIL RSI Chart

DTIL Valuation

Market Cap

65.1M

Price/Earnings (Trailing)

-2.35

Price/Sales (Trailing)

1.13

Price/Free Cashflow

-0.91

DTIL Price/Sales (Trailing)

DTIL Profitability

Return on Equity

-74.37%

Return on Assets

-14.98%

Free Cashflow Yield

-110.03%

DTIL Fundamentals

DTIL Revenue

Revenue (TTM)

57.5M

Rev. Growth (Yr)

100.27%

Rev. Growth (Qtr)

149.84%

DTIL Earnings

Earnings (TTM)

-27.7M

Earnings Growth (Yr)

134.27%

Earnings Growth (Qtr)

152.72%

Breaking Down DTIL Revenue

52 Week Range

9.97
(Low)(High)

Last 7 days

-15.4%

Last 30 days

-28.1%

Last 90 days

-19.0%

Trailing 12 Months

-46.0%

How does DTIL drawdown profile look like?

DTIL Financial Health

Current Ratio

4.82

Debt/Equity

0.6

Debt/Cashflow

-3.22

DTIL Investor Care

Shares Dilution (1Y)

82.58%

Diluted EPS (TTM)

-7.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202457.5M000
202330.6M46.5M52.3M48.7M
2022102.5M37.5M20.8M25.1M
202133.6M101.4M118.0M115.5M
202023.8M19.5M22.0M24.3M
201914.8M18.3M20.7M22.2M
201800010.9M

Tracking the Latest Insider Buys and Sells of Precision BioSciences Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 10, 2024
smith j. jefferson
sold
-589
11.79
-50.00
chief research officer
Jun 10, 2024
scimeca dario
sold
-1,096
11.79
-93.00
general counsel and secretary
Jun 07, 2024
scimeca dario
acquired
-
-
301
general counsel and secretary
Jun 07, 2024
smith j. jefferson
acquired
-
-
163
chief research officer
Jun 07, 2024
kelly john alexander
acquired
-
-
454
chief financial officer
May 08, 2024
kelly john alexander
acquired
100,008
12.00
8,334
chief financial officer
May 08, 2024
smith j. jefferson
acquired
9,996
12.00
833
chief research officer
May 08, 2024
scimeca dario
acquired
9,996
12.00
833
general counsel and secretary
May 08, 2024
amoroso michael
acquired
100,008
12.00
8,334
president and ceo
May 04, 2024
frankel stanley
acquired
-
-
4,202
-

1–10 of 50

Which funds bought or sold DTIL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 03, 2024
HAMILTON LANE ADVISORS LLC
sold off
-100
-57,740
-
-%
May 15, 2024
STATE STREET CORP
sold off
-100
-89,187
-
-%
May 15, 2024
Blue Owl Capital Holdings LP
new
-
274,183
274,183
0.06%
May 15, 2024
Blue Owl Capital Holdings LP
sold off
-100
-221,420
-
-%
May 15, 2024
MORGAN STANLEY
sold off
-100
-121,964
-
-%
May 15, 2024
MORGAN STANLEY
new
-
159,452
159,452
-%
May 15, 2024
Engineers Gate Manager LP
sold off
-100
-11,205
-
-%
May 15, 2024
Aquilo Capital Management, LLC
new
-
5,226,570
5,226,570
3.92%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
5,275
5,275
-%
May 15, 2024
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-41,422
-
-%

1–10 of 49

Are Funds Buying or Selling DTIL?

Are funds buying DTIL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own DTIL
No. of Funds

Unveiling Precision BioSciences Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Mar 18, 2024
aquilo capital management, llc
7.1%
466,767
SC 13G
Mar 14, 2024
perceptive advisors llc
7.9%
5e+05
SC 13G
Mar 11, 2024
janus henderson group plc
8.0%
511,108
SC 13G
Feb 14, 2024
great point partners llc
0%
0
SC 13G/A
Feb 09, 2024
capital world investors
4.2%
5,119,458
SC 13G/A
Feb 05, 2024
tang capital partners lp
5.2%
6,400,000
SC 13G
Feb 27, 2023
great point partners llc
7.30%
8,099,799
SC 13G
Feb 14, 2023
great point partners llc
3.43%
3,801,305
SC 13G/A
Feb 13, 2023
capital world investors
6.1%
6,715,043
SC 13G/A
Feb 09, 2023
vanguard group inc
3.94%
4,373,367
SC 13G/A

Recent SEC filings of Precision BioSciences Inc

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 10, 2024
144
Notice of Insider Sale Intent
Jun 10, 2024
8-K
Current Report
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading
Jun 06, 2024
4
Insider Trading

Peers (Alternatives to Precision BioSciences Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
51.1B
6.8B
-18.41% 10.61%
-8.56
7.46
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
21.0B
2.0B
9.73% -16.82%
-63.12
10.46
75.20% 68.82%
15.9B
2.5B
9.61% -12.35%
77.43
6.44
13.74% 186.89%
14.2B
3.8B
8.63% 2.12%
19.04
3.77
8.58% 129.81%
MID-CAP
5.1B
107.9M
-6.63% 69.33%
-9.37
48.09
54.84% -28.31%
4.6B
524.1M
-12.71% -56.08%
-11.07
8.82
394.93% 39.61%
3.6B
251.0M
-0.36% -15.32%
-12.24
14.45
73.58% -86.73%
3.2B
240.7M
1.47% -28.24%
-6.69
12.77
-1.03% -213.92%
2.5B
813.8M
-3.10% -36.23%
-1.5K
3.11
56.43% 98.83%
2.0B
996.6M
-10.70% 95.81%
-4.94
1.98
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-3.41% 18.74%
28.28
4.48
60.38% -34.49%
453.7M
881.7K
-5.58% 440.76%
-13.44
481.06
-77.61% 33.36%
209.4M
4.2M
-28.18% 49.63%
-1.68
50.33
-66.30% 48.24%
18.2M
2.1M
-6.22% 224.62%
-0.79
7.61
-13.45% 69.54%

Precision BioSciences Inc News

Latest updates
Defense World15 hours ago
Yahoo News Malaysia20 Jun 202407:18 pm

Precision BioSciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue149.8%17,5847,03813,12019,7898,78010,5987,3633,8203,3176,33924,03668,80516,3498,8467,3631,0786,9986,5224,8655,3895,462
Operating Expenses24.4%21,77117,49925,48331,77622,13412,02422,03933,37430,65237,06335,57847,17335,09132,32633,40733,88634,49428,38326,84329,26024,956
  S&GA Expenses-1.3%8,4288,5399,6339,83011,0869,95510,28110,43810,68010,5939,6389,9389,4989,2008,5348,7039,6158,4797,0526,5004,995
  R&D Expenses48.9%13,3438,96015,85021,94611,0482,07011,75822,93619,97226,47025,94037,23525,59323,12624,87325,18324,87919,90419,79122,76019,961
Interest Expenses-0.9%57457957655352248640517842.0053.0055.0024.00--------182
Net Income152.7%8,588-16,289-8,079-11,891-25,060-28,488-23,946-31,035-28,168-22,290-11,27921,656-18,689-23,453-26,016-32,701-26,836-20,916-20,742-19,436-31,783
Net Income Margin61.8%-0.48*-1.26*-1.41*-1.92*-3.55*-4.45*-5.06*-2.47*-0.39*-0.26*-0.27*-0.46*---------
Free Cashflow-125.3%-18,981-8,423-23,093-21,134-31,464-21,84329,186-24,224-28,872-23,681-23,905-31,339---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets15.6%185160164182205238272297181211227230262150169184214235260272167
  Current Assets17.9%161136146148169199225248134162183188219106123137167194220237137
    Cash Equivalents18.1%13811712213815819021218411614416017419390.00104127154181206226116
  Net PPE-16.6%5.006.009.0018.0019.0012.0022.0023.0024.0025.0032.0033.0034.0035.0036.0038.0039.0040.0039.0033.0028.00
Liabilities4.7%14814113514816417818719411212012613020310610599.0099.0097.0010598.00156
  Current Liabilities-33.3%33.0050.0051.0056.0047.0060.0061.0054.0029.0036.0036.0036.0064.0043.0042.0034.0024.0027.0024.0016.0071.00
  Long Term Debt-----22.0022.0022.0022.002.002.00-----------
Shareholder's Equity97.3%37.0019.0029.0034.0040.0060.0084.0010370.0091.0010110159.0044.0064.0086.0011513815617411.00
  Retained Earnings1.8%-481-489-473-465-453-428-399-375-344-316-294-283-304-286-262-236-203-177-156-135-115
  Additional Paid-In Capital1.9%519509503500495490485480415409397385365331327323320316313310128
Shares Outstanding66.1%7.004.004.004.004.004.004.002.002.002.002.002.00---------
Float----59.00---170---664---383---589-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-125.3%-18,981-8,423-23,093-21,134-31,464-21,84329,186-24,224-28,872-23,681-23,905-31,33968,072-13,452-22,223-25,801-25,910-20,556-13,977-16,575-19,907
  Share Based Compensation-2.1%2,9062,9693,1053,8744,0924,5365,1335,1384,3904,4354,5513,8963,6323,8543,7093,1183,1052,6212,4912,2791,549
Cashflow From Investing-161.9%-26.0042.007,564-1,056-721-632-1,090-779-818-1,505-1,483-1,690-1,125-1,096-1,047-1,785-1,103-5,529-5,918-8,137-5,082
Cashflow From Financing1317.8%40,0952,828-34.001,852741--18092,9162,2498,37811,91613,51236,71519853228531470661.00134,31238,295
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

DTIL Income Statement

2024-03-31
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Revenue$ 17,584$ 8,780
Operating expenses  
Research and development13,34311,048
General and administrative8,42811,086
Total operating expenses21,77122,134
Operating loss(4,187)(13,354)
Other income (expense):  
Gain (loss) from equity method investment1,713(1,341)
Loss on changes in fair value(348)(769)
Gain on change in fair value of warrant liability10,386 
Interest expense(574)(522)
Interest income1,6632,043
Loss on disposal of assets(65)(7)
Total other income (expense)12,775(596)
Income (loss) from continuing operations8,588(13,950)
Loss from discontinued operations (11,110)
Net income (loss)$ 8,588$ (25,060)
Net income (loss) per share - Basic$ 1.7$ (6.75)
Net income (loss) per share - Diluted$ 1.7$ (6.75)
Weighted average common shares outstanding - Basic5,060,9783,709,894
Weighted average common shares outstanding - Diluted5,063,4063,709,894

DTIL Balance Sheet

2024-03-31
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 137,766$ 116,678
Accounts receivable390901
Prepaid expenses9,2545,977
Convertible note receivable11,55311,897
Assets held for sale378487
Contract asset1,359 
Other current assets128419
Total current assets160,828136,359
Property, equipment, and software—net5,2866,338
Intangible assets—net386400
Right-of-use assets—net7,9798,263
Investment in equity securities3,2063,206
Note receivable—net6,8184,990
Other assets238225
Total assets184,741159,781
Current liabilities:  
Accounts payable1,1362,968
Accrued compensation1,2204,978
Accrued research and development expenses6561,557
Deferred revenue2,40612,035
Loan payable-net22,46022,412
Lease liabilities1,1821,133
Other current liabilities2,7722,391
Current liabilities of discontinued operations1,5062,513
Total current liabilities33,33849,987
Deferred revenue74,76673,082
Lease liabilities7,4117,723
Warrant liability22,020 
Contract liabilities10,00010,000
Noncurrent liabilities of discontinued operations 128
Total liabilities147,535140,920
Commitments and contingencies (Note 4)
Stockholders’ equity:  
Preferred stock, $0.0001 par value- 10,000,000 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued and outstanding as of March 31, 2024 and December 31, 2023
Common stock; $0.000005 par value - 200,000,000 shares authorized as of March 31, 2024 and December 31,2023; 6,943,254 shares issued and 6,916,239 shares outstanding as of March 31, 2024; 4,191,053 shares issued and 4,164,038 shares outstanding as of December 31, 202311
Additional paid-in capital519,200509,443
Accumulated deficit(481,043)(489,631)
Treasury stock(952)(952)
Total stockholders’ equity37,20618,861
Total liabilities and stockholders’ equity$ 184,741$ 159,781
DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
 CEO
 WEBSITEprecisionbiosciences.com
 INDUSTRYBiotechnology
 EMPLOYEES192

Precision BioSciences Inc Frequently Asked Questions


What is the ticker symbol for Precision BioSciences Inc? What does DTIL stand for in stocks?

DTIL is the stock ticker symbol of Precision BioSciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Precision BioSciences Inc (DTIL)?

As of Fri Jun 21 2024, market cap of Precision BioSciences Inc is 65.1 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers.

What is the fair value of DTIL stock?

You can check DTIL's fair value in chart for subscribers. The fair value of Precision BioSciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Precision BioSciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for DTIL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Precision BioSciences Inc a good stock to buy?

The fair value guage provides a quick view whether DTIL is over valued or under valued. Whether Precision BioSciences Inc is cheap or expensive depends on the assumptions which impact Precision BioSciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for DTIL.

What is Precision BioSciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 21 2024, DTIL's PE ratio (Price to Earnings) is -2.35 and Price to Sales (PS) ratio is 1.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. DTIL PE ratio will change depending on the future growth rate expectations of investors.